Bei diesem Impfstoffkandidaten handelt es sich um ein inaktiviertes Virus.
Weitere frühere Infos auch zum Impfstoff finden sich unter dem allgemeinen Punkt "Impfungen gegen SARS-CoV-2".
Sinopharm has two candidates among five Chinese trial vaccines in phase 3 clinical trials globally. The company didn't clarify which vaccine has been approved by Beijing.
It's the first company to receive conditional approval from Chinese authorities, which allows a wider proportion of people aged between 18 to 59 to be immunised.
However, pregnant women and people who have cancer, severe liver and kidney conditions, uncontrollable high-blood pressure or diabetes are prohibited from the vaccination program for now.
People who have recently received vaccines for the Human Papilloma Virus (HPV) are also recommended to avoid taking the jab for safety reasons.